These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

93 related articles for article (PubMed ID: 30271215)

  • 1. Gemcitabine and docetaxel as second-line chemotherapy in elderly patients with metastatic urothelial carcinoma: a retrospective analysis.
    Naiki T; Iida K; Etani T; Nagai T; Tanaka Y; Sugiyama Y; Ando R; Hamamoto S; Banno R; Nagata D; Kawai N; Yasui T
    Cancer Manag Res; 2018; 10():3669-3677. PubMed ID: 30271215
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Chronological transition in outcome of second-line treatment in patients with metastatic urothelial cancer after pembrolizumab approval: a multicenter retrospective analysis.
    Isobe T; Naiki T; Sugiyama Y; Naiki-Ito A; Nagai T; Etani T; Nozaki S; Iida K; Noda Y; Shimizu N; Tomiyama N; Banno R; Kubota H; Hamamoto S; Ando R; Kawai N; Yasui T
    Int J Clin Oncol; 2022 Jan; 27(1):165-174. PubMed ID: 34633579
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Phase II Study of Weekly Docetaxel as Second-Line Chemotherapy in Patients With Metastatic Urothelial Carcinoma.
    Kim YS; Lee SI; Park SH; Park S; Hwang IG; Lee SC; Sun JM; Lee J; Lim HY
    Clin Genitourin Cancer; 2016 Feb; 14(1):76-81. PubMed ID: 26454620
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Skeletal Muscle Mass Reduction Velocity as a Simple Prognostic Indicator for Patients with Metastatic Urothelial Carcinoma Receiving Second-Line Chemotherapy.
    Nagai T; Naiki T; Iida K; Nozaki S; Etani T; Sugiyama Y; Ando R; Yanase T; Chaya R; Moritoki Y; Kobayashi D; Akita H; Okamura T; Yasui T
    Asian Pac J Cancer Prev; 2019 Oct; 20(10):2995-3000. PubMed ID: 31653146
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A pilot study of gemcitabine and paclitaxel as third-line chemotherapy in metastatic urothelial carcinoma.
    Naiki T; Iida K; Kawai N; Etani T; Ando R; Nagai T; Tanaka Y; Hamamoto S; Hamakawa T; Akita H; Sugiyama Y; Yasui T
    J Rural Med; 2017 Nov; 12(2):105-111. PubMed ID: 29255527
    [No Abstract]   [Full Text] [Related]  

  • 6. Low Geriatric Nutritional Risk Index as a Poor Prognostic Marker for Second-Line Pembrolizumab Treatment in Patients with Metastatic Urothelial Carcinoma: A Retrospective Multicenter Analysis.
    Etani T; Naiki T; Sugiyama Y; Nagai T; Iida K; Noda Y; Shimizu N; Tasaki Y; Mimura Y; Okada T; Banno R; Kubota H; Hamamoto S; Ando R; Kawai N; Yasui T
    Oncology; 2020; 98(12):876-883. PubMed ID: 32862183
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Gemcitabine maintenance versus observation after first-line chemotherapy in patients with metastatic urothelial carcinoma: a retrospective study.
    Kim H; Lee SH; Kim DH; Lee JY; Hong SH; Ha US; Kim IH
    Transl Androl Urol; 2020 Oct; 9(5):2113-2121. PubMed ID: 33209674
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative Study of the Safety and Efficacy of First-Line Cisplatin and Carboplatin Chemotherapy in Elderly Patients with Metastatic Urothelial Carcinoma.
    Huang SY; Wu CC; Hsieh MC; Rau KM; Chiang PH; Sung MT; Luo HL; Huang CC; Huang CH; Liu JM; Su HY
    Oncology; 2020; 98(3):146-153. PubMed ID: 31794969
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Combination of Anlotinib and Gemcitabine/Docetaxel in Patients with Metastatic Osteosarcoma Who Have Failed Standard Chemotherapy.
    Wang T; Lin F; Huang Y; Qian G; Yu W; Hu H; Ji T; Tang L; Yao Y
    Cancer Manag Res; 2022; 14():2945-2952. PubMed ID: 36217441
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Exploratory analysis of front-line therapies in REVEL: a randomised phase 3 study of ramucirumab plus docetaxel versus docetaxel for the treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy.
    Garon EB; Scagliotti GV; Gautschi O; Reck M; Thomas M; Iglesias Docampo L; Kalofonos H; Kim JH; Gans S; Brustugun OT; Orlov SV; Cuyun Carter G; Zimmermann AH; Oton AB; Alexandris E; Lee P; Wolff K; Stefaniak VJ; Socinski MA; Pérol M
    ESMO Open; 2020 Jan; 5(1):. PubMed ID: 31958290
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Atezolizumab with or without chemotherapy in metastatic urothelial cancer (IMvigor130): a multicentre, randomised, placebo-controlled phase 3 trial.
    Galsky MD; Arija JÁA; Bamias A; Davis ID; De Santis M; Kikuchi E; Garcia-Del-Muro X; De Giorgi U; Mencinger M; Izumi K; Panni S; Gumus M; Özgüroğlu M; Kalebasty AR; Park SH; Alekseev B; Schutz FA; Li JR; Ye D; Vogelzang NJ; Bernhard S; Tayama D; Mariathasan S; Mecke A; Thåström A; Grande E;
    Lancet; 2020 May; 395(10236):1547-1557. PubMed ID: 32416780
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase II study of lapatinib and capecitabine in second-line treatment for metastatic pancreatic cancer.
    Wu Z; Gabrielson A; Hwang JJ; Pishvaian MJ; Weiner LM; Zhuang T; Ley L; Marshall JL; He AR
    Cancer Chemother Pharmacol; 2015 Dec; 76(6):1309-14. PubMed ID: 26507197
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ramucirumab plus docetaxel versus placebo plus docetaxel in patients with locally advanced or metastatic urothelial carcinoma after platinum-based therapy (RANGE): a randomised, double-blind, phase 3 trial.
    Petrylak DP; de Wit R; Chi KN; Drakaki A; Sternberg CN; Nishiyama H; Castellano D; Hussain S; Fléchon A; Bamias A; Yu EY; van der Heijden MS; Matsubara N; Alekseev B; Necchi A; Géczi L; Ou YC; Coskun HS; Su WP; Hegemann M; Percent IJ; Lee JL; Tucci M; Semenov A; Laestadius F; Peer A; Tortora G; Safina S; Del Muro XG; Rodriguez-Vida A; Cicin I; Harputluoglu H; Widau RC; Liepa AM; Walgren RA; Hamid O; Zimmermann AH; Bell-McGuinn KM; Powles T;
    Lancet; 2017 Nov; 390(10109):2266-2277. PubMed ID: 28916371
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ramucirumab plus docetaxel versus placebo plus docetaxel in patients with locally advanced or metastatic urothelial carcinoma after platinum-based therapy (RANGE): overall survival and updated results of a randomised, double-blind, phase 3 trial.
    Petrylak DP; de Wit R; Chi KN; Drakaki A; Sternberg CN; Nishiyama H; Castellano D; Hussain SA; Fléchon A; Bamias A; Yu EY; van der Heijden MS; Matsubara N; Alekseev B; Necchi A; Géczi L; Ou YC; Coskun HS; Su WP; Bedke J; Gakis G; Percent IJ; Lee JL; Tucci M; Semenov A; Laestadius F; Peer A; Tortora G; Safina S; Garcia Del Muro X; Rodriguez-Vida A; Cicin I; Harputluoglu H; Tagawa ST; Vaishampayan U; Aragon-Ching JB; Hamid O; Liepa AM; Wijayawardana S; Russo F; Walgren RA; Zimmermann AH; Hozak RR; Bell-McGuinn KM; Powles T;
    Lancet Oncol; 2020 Jan; 21(1):105-120. PubMed ID: 31753727
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Do patients with metastatic urothelial carcinoma benefit from docetaxel as second-line chemotherapy?
    Morales-Barrera R; Suárez C; Valverde C; Nuñez I; Maldonado X; Morote J; Carles J
    Clin Transl Oncol; 2014 Jan; 16(1):102-6. PubMed ID: 23606355
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Docetaxel As Monotherapy or Combined With Ramucirumab or Icrucumab in Second-Line Treatment for Locally Advanced or Metastatic Urothelial Carcinoma: An Open-Label, Three-Arm, Randomized Controlled Phase II Trial.
    Petrylak DP; Tagawa ST; Kohli M; Eisen A; Canil C; Sridhar SS; Spira A; Yu EY; Burke JM; Shaffer D; Pan CX; Kim JJ; Aragon-Ching JB; Quinn DI; Vogelzang NJ; Tang S; Zhang H; Cavanaugh CT; Gao L; Kauh JS; Walgren RA; Chi KN
    J Clin Oncol; 2016 May; 34(13):1500-9. PubMed ID: 26926681
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cetuximab, docetaxel, and cisplatin versus platinum, fluorouracil, and cetuximab as first-line treatment in patients with recurrent or metastatic head and neck squamous-cell carcinoma (GORTEC 2014-01 TPExtreme): a multicentre, open-label, randomised, phase 2 trial.
    Guigay J; Aupérin A; Fayette J; Saada-Bouzid E; Lafond C; Taberna M; Geoffrois L; Martin L; Capitain O; Cupissol D; Castanie H; Vansteene D; Schafhausen P; Johnson A; Even C; Sire C; Duplomb S; Evrard C; Delord JP; Laguerre B; Zanetta S; Chevassus-Clément C; Fraslin A; Louat F; Sinigaglia L; Keilholz U; Bourhis J; Mesia R; ; ;
    Lancet Oncol; 2021 Apr; 22(4):463-475. PubMed ID: 33684370
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The efficiency of single agent docetaxel in patients with platinum-refractory non-small cell lung carcinoma.
    Uygun K; Aksu G; Cicin I; Karagol H; Kocak Z; Fayda M; Binici A; Uzunoglu F
    Med Oncol; 2008; 25(4):408-14. PubMed ID: 18320363
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Second-line docetaxel-based chemotherapy after failure of fluorouracil-based first-line treatment for advanced esophageal squamous cell carcinoma.
    Song Z; Zhang Y
    Onco Targets Ther; 2014; 7():1875-81. PubMed ID: 25342911
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of response to prior chemotherapy in patients with advanced urothelial carcinoma receiving second-line therapy: implications for trial design.
    Pond GR; Bellmunt J; Fougeray R; Choueiri TK; Qu AQ; Niegisch G; Albers P; Di Lorenzo G; Salhi Y; Galsky MD; Agarwal N; Necchi A; Sonpavde G
    Clin Genitourin Cancer; 2013 Dec; 11(4):495-500. PubMed ID: 23800847
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.